Texray has announced that interventional radiologist Ziv J Haskal (University of Virginia School of Medicine, Charlottesville, USA) has joined the company’s clinical and scientific advisory board.
The appointment of Haskal comes as Texray formalises its clinical and scientific network in response to growing demand for ERPDs, stated the company. Texray also recently announced the appointment of interventional cardiologist Morton J Kern (University of California, Irvine, Irvine, USA) to its clinical and scientific advisory board.
According to the company, Haskal was among the first to describe an association between occupational radiation exposure and cataracts in endovascular specialists. The company highlights Haskal’s previous two-terms as editor-in-chief of the Journal of Vascular and Interventional Radiology (JVIR), as well as his numerous gold medal and societal awards, and honorary fellowships in years previous.
Texray stated that its technology platform is used in its personal protective equipment—the HeadPeace and the MindPeace devices—as well as in its MasterPeace, which the company states, is recognised as an enhanced radiation protective device (ERPD) in the multisociety expert consensus statement on enhanced radiation protection.
“Radiation safety is a cornerstone of endovascular practice, yet the burden runs two ways: Exposure accumulates quietly across a career, as does the weight worn to prevent it,” commented Haskal in Texray’s press release. “There is no denying the musculoskeletal strain, disability, and incomplete shielding that providers experience from long careers wearing protective gear.”
Haskal continued: “ERPDs represent a critical next evolutionary safety step, but they have to accomplish this without compromising patient access or clinical workflow. Texray listens to clinicians and allows the science to set the pace. They are building the room for what modern radiation protection should be—for all and every specialty working with fluoroscopy.”
Petra Apell, founder and chief executive officer (CEO) of Texray, stated in the press release: “Interventional radiologists spend their careers very close to the radiation source. I value Haskal’s extensive research experience and his deep understanding of the evidence required before a new technology can earn clinical trust. This closely reflects our values at Texray. If clinical teams are to have the freedom to choose an apron-free working environment in the future, that choice must be supported by thorough, robust clinical evidence.”
